Catherine Klersy1, Giuseppe Boriani2, Annalisa De Silvestri1, Georges H Mairesse3, Frieder Braunschweig4, Valeria Scotti5, Anna Balduini5, Martin R Cowie5, Francisco Leyva6. 1. Service of Biometry & Statistics, IRCCS Fondazione Policlinico S Matteo, Pavia, Italy. 2. Cardiology Department, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy. 3. Cliniques du Sud Luxembourg, Arlon, Belgium. 4. Karolinska University Hospital, Stockholm, Sweden. 5. Centre for Scientific Documentation, IRCCS Fondazione Policlinico S Matteo, Pavia, Italy. 6. Aston Medical Research Institute, Aston Medical School, Aston University, Birmingham, UK.
Abstract
AIMS: Implantable device telemonitoring (DTM) is a diagnostic adjunct to traditional face-to-face hospital visits. Remote device follow-up and earlier diagnoses facilitated by DTM should reduce healthcare utilization. We explored whether DTM reduces healthcare utilization over standard of care (SoC), without compromising patient outcomes. METHODS AND RESULTS: This systematic review and meta-analysis of 11 randomized controlled trials on DTM in patients with heart failure consisted of 5702 patients, with a median of 117 [interquartile range (IQR) 76-331] patients per study [age 65 years (IQR 63-67)] and follow-up range of 12-36 months. DTM was associated with a reduction in total number of visits [planned, unplanned, and emergency room (ER)] [relative risk (RR) 0.56; 95% confidence interval (CI) 0.43-0.73, P < 0.001]. Rates of cardiac hospitalizations (RR 0.96; 95% CI 0.82-1.12, P = 0.60) and the composite endpoints of ER, unplanned hospital visits, or hospitalizations (RR 0.99; 95% CI 0.68-1.43, P = 0.96) was similar between the DTM and the SoC groups. An increase in the total number of ER or unscheduled visits (RR 1.37; 95% CI 1.11-1.70, P = 0.004) was observed. This effect was consistent and statistically significant for all studies. Total and cardiac mortality were similar between the groups (DTM RR 0.90; 95% CI 0.69-1.16, P = 0.41; and DTM RR 0.93; 95% CI 0.51-1.69, P = 0.80). Monetary costs favoured DTM (10-55% reduction in five studies). CONCLUSIONS: Compared with SoC, DTM is associated with a marked reduction in planned hospital visits. In addition, DTM was associated with lower monetary costs, despite a modest increase in unplanned hospital and ER visits. DTM did not compromise survival.
AIMS: Implantable device telemonitoring (DTM) is a diagnostic adjunct to traditional face-to-face hospital visits. Remote device follow-up and earlier diagnoses facilitated by DTM should reduce healthcare utilization. We explored whether DTM reduces healthcare utilization over standard of care (SoC), without compromising patient outcomes. METHODS AND RESULTS: This systematic review and meta-analysis of 11 randomized controlled trials on DTM in patients with heart failure consisted of 5702 patients, with a median of 117 [interquartile range (IQR) 76-331] patients per study [age 65 years (IQR 63-67)] and follow-up range of 12-36 months. DTM was associated with a reduction in total number of visits [planned, unplanned, and emergency room (ER)] [relative risk (RR) 0.56; 95% confidence interval (CI) 0.43-0.73, P < 0.001]. Rates of cardiac hospitalizations (RR 0.96; 95% CI 0.82-1.12, P = 0.60) and the composite endpoints of ER, unplanned hospital visits, or hospitalizations (RR 0.99; 95% CI 0.68-1.43, P = 0.96) was similar between the DTM and the SoC groups. An increase in the total number of ER or unscheduled visits (RR 1.37; 95% CI 1.11-1.70, P = 0.004) was observed. This effect was consistent and statistically significant for all studies. Total and cardiac mortality were similar between the groups (DTM RR 0.90; 95% CI 0.69-1.16, P = 0.41; and DTM RR 0.93; 95% CI 0.51-1.69, P = 0.80). Monetary costs favoured DTM (10-55% reduction in five studies). CONCLUSIONS: Compared with SoC, DTM is associated with a marked reduction in planned hospital visits. In addition, DTM was associated with lower monetary costs, despite a modest increase in unplanned hospital and ER visits. DTM did not compromise survival.
Authors: Giuseppe D'Ancona; Erdal Safak; Jochen Senges; Matthias Hochadel; Van Luyen Nguyen; Christian Perings; Werner Jung; Stefan Spitzer; Lars Eckardt; Johannes Brachmann; Karlheinz Seidl; Hans Ulrich Hink; Hüseyin Ince; Jasmin Ortak Journal: Clin Res Cardiol Date: 2017-06-07 Impact factor: 5.460
Authors: Michael Gruska; Gerhard Aigner; Johann Altenberger; Dagmar Burkart-Küttner; Lukas Fiedler; Marianne Gwechenberger; Peter Lercher; Martin Martinek; Michael Nürnberg; Gerhard Pölzl; Gerold Porenta; Stefan Sauermann; Christoph Schukro; Daniel Scherr; Clemens Steinwender; Markus Stühlinger; Alexander Teubl Journal: Wien Klin Wochenschr Date: 2020-12-01 Impact factor: 1.704
Authors: Ahmad Al-Abdouh; Mohammed Mhanna; Mohammad As Sayaideh; Mahmoud Barbarawi; Waiel Abusnina; Ahmad Jabri; Hossam Alzu'bi; Anan Abu Rmilah; Ikram-Ul Haq; Ashish Kumar; Taha Ahmed; Erin D Michos; Gurukripa N Kowlgi; Abhishek Deshmukh Journal: Curr Heart Fail Rep Date: 2022-10-07
Authors: Eric L Wallace; Mitchell H Rosner; Mark Dominik Alscher; Claus Peter Schmitt; Arsh Jain; Francesca Tentori; Catherine Firanek; Karen S Rheuban; Jose Florez-Arango; Vivekanand Jha; Marjorie Foo; Koen de Blok; Mark R Marshall; Mauricio Sanabria; Timothy Kudelka; James A Sloand Journal: Kidney Int Rep Date: 2017-07-29